RenovoRx Initiates Patient Enrollment At University Of Texas Southwestern Medical Center For Pivotal Phase III TIGeR-PaC Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
RenovoRx has initiated patient enrollment at the University of Texas Southwestern Medical Center for its pivotal Phase III TIGeR-PaC clinical trial. The trial aims to evaluate the safety and efficacy of RenovoRx's TIGeR-PaC therapy in treating locally advanced pancreatic cancer.
June 01, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RenovoRx initiates patient enrollment for its Phase III TIGeR-PaC clinical trial, potentially leading to positive outcomes for the company's therapy in treating pancreatic cancer.
The initiation of patient enrollment for RenovoRx's Phase III TIGeR-PaC clinical trial is a significant milestone for the company. Positive results from the trial could lead to regulatory approval and commercialization of the therapy, which would benefit RNXT's stock price in the short term. The news is highly relevant and important for investors in RNXT, as the success of the trial could have a significant impact on the company's future growth and revenue.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100